Diabetes Clinical Trials in Louisville, KY

18 recruiting studies within 50 miles

Phase

Trial	Phase	Sponsor	Dist.
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)	Phase 3	Eli Lilly and Company	<1 mi
Gastroparesis Registry 4	—	Johns Hopkins Bloomberg School of Public Health	<1 mi
Study of Enterra Programming with Nocturnal Cycling in Gastroparetics	N/A	Enterra Medical, Inc.	<1 mi
Study of Enhanced Programming Stimulation with the Enterra® Therapy System	N/A	Enterra Medical, Inc.	<1 mi
A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults	Phase 3	Eli Lilly and Company	<1 mi
A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome	Phase 3	NewAmsterdam Pharma	<1 mi
A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight	Phase 3	Eli Lilly and Company	<1 mi
Effect of Inhaled Technosphere Insulin vs RAA Insulin on Exercise-Induced Hypoglycemia in Adults With T1D Using Automated Insulin Delivery	N/A	Jaeb Center for Health Research	<1 mi
A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes	Phase 3	Novo Nordisk A/S	<1 mi
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)	Phase 3	Eli Lilly and Company	<1 mi
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight	Phase 3	Eli Lilly and Company	<1 mi
Registry for Stage 2 Type 1 Diabetes	—	Sanofi	<1 mi
Resistance Training in Type 1 Diabetes Mellitus	N/A	University of Louisville	<1 mi
A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma	Phase 2	Children's Oncology Group	<1 mi
VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)	Phase 3	Viking Therapeutics, Inc.	<1 mi
A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events	N/A	Cleerly, Inc.	<1 mi
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis	Phase 2/3	CSL Behring	<1 mi
Fenofibrate for Prevention of DR Worsening	Phase 3	Jaeb Center for Health Research	4 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.